Health News Releases

July 30, 2018 11:35

KOHI concluded final course of ‘Multi-year Competency enhancement of Diagnosis and Treatment of ASD for Children for Bangladesh’

Korea Human Resource Development Institute for Health and Welfare(KOHI) announced that it had successfully finished ‘Multi-year Competency enhancement of Diagnosis and Treatment of Autism Spectrum Dis

July 26, 2018 13:45

Takeda Announces Phase 3 Trial of ALUNBRIG® (brigatinib) Met Primary Endpoint Demonstrating Superiority in Progression-Free Survival Versus Crizotinib in Patients with ALK+ Advanced NSCLC Who are ALK Inhibitor Naïve

Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the global, randomized, Phase 3 ALTA-1L (ALK in Lung Cancer Trial of AP26113 in 1st Line) trial met its primary endpoint at the f

July 25, 2018 15:35

Banyan Biomarkers Announces Publication of ALERT-TBI Clinical Study Results in The Lancet Neurology

Banyan Biomarkers, Inc., a pioneer in developing biomarkers for traumatic brain injury (TBI), today announced the publication of the results for the ALERT-TBI study, an international, multicenter clin

July 24, 2018 09:05

Ferring’s Heat-Stable Carbetocin Could Save Thousands of Women’s Lives by Preventing Excessive Bleeding after Childbirth

Ferring Pharmaceuticals today announced new data demonstrating that its heat-stable formulation of carbetocin is as effective as the current standard of care, oxytocin, for the prevention of excessive

July 20, 2018 10:10

Boehringer Ingelheim and Lilly announce Trajenta®’s CARMELINA® cardiovascular outcome trial met its primary endpoint

CARMELINA®1 (CArdiovascular safety and Renal Microvascular outcomE with LINAgliptin in patients with type 2 diabetes at high vascular risk) met its primary endpoint, defined as time to first occurrenc

July 19, 2018 18:40

New Phase 3 Data Show Investigational Subcutaneous Formulation of Vedolizumab Meets Primary Endpoint in Achieving Clinical Remission at Week 52 in Patients with Moderately to Severely Active Ulcerative Colitis

Takeda Pharmaceutical Company Limited [TSE:4502] (“Takeda”) today announced top-line results from the VISIBLE 1 clinical trial evaluating the efficacy and safety of an investigational subcutaneous (SC

July 19, 2018 17:25

Emmaus Life Sciences Announces the New England Journal of Medicine has Published the Phase 3 Trial Results of Endari™ (L-Glutamine Oral Powder) in Sickle Cell Disease

VIEW E-MEDIA KIT (http://bit.ly/2zUquOI) - Emmaus Life Sciences, Inc. (Emmaus) announced today that the New England Journal of Medicine (NEJM) has published the results of its 48-week phase 3 clinical

July 18, 2018 16:15

22nd Century Announces the Immediate Feasibility of the FDA’s Nicotine Reduction Plan

22nd Century Group, Inc. (NYSE American:XXII), a plant biotechnology company that is a leader in tobacco harm reduction and Very Low Nicotine tobacco, yesterday responded to the Advance Notice of Prop

July 17, 2018 12:00

New Study Investigates the Utility of Masimo PVi® as Part of Goal-Directed Fluid Management in Patients Undergoing Colorectal Surgery

Masimo (NASDAQ: MASI) announced today the findings of a recently published study in which researchers at Kocaeli University in Turkey compared the performance of conventional fluid management (CFM) to

July 13, 2018 16:20

ResMed, Verily to Form Joint Venture to Help Reach Millions of Untreated Sleep Apnea Sufferers

ResMed (NYSE: RMD, ASX: RMD), a global leader in sleep apnea treatment and connected health solutions, and Verily, an Alphabet company, today announced their agreement to form a new joint venture.

July 13, 2018 13:25

Dr. Yu-mi Jung of Magic Kiss Dental Clinic, Patented for orthodontic technique to improve gummy smile

Dr. Yu-mi Jung of Magic Kiss Dental Clinic acquired a patent for the technique to improve gummy smile and correct teeth at the same time. The core of this patent is that it allows for the resolutio

July 12, 2018 18:00

Phase 3 Trial of NINLARO® (ixazomib) as Maintenance Therapy Met Primary Endpoint Demonstrating Statistically Significant Improvement in Progression-Free Survival in Patients with Multiple Myeloma Post-Transplant

Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the randomized, Phase 3 TOURMALINE-MM3 study met its primary endpoint, demonstrating single-agent oral NINLARO® (ixazomib) as a m

July 12, 2018 16:15

EUSA Pharma: NICE Approves the Targeted Cancer Immunotherapy, QARZIBA®▼ (dinutuximab beta) to Treat Children with High-Risk Neuroblastoma

EUSA Pharma today welcomed a decision by the National Institute for Health and Care Excellence (NICE) to recommend the use of the targeted cancer immunotherapy, QARZIBA® (dinutuximab beta) to treat ch

July 11, 2018 17:20

President Clinton to Deliver Closing Keynote Address on Eliminating Preventable Deaths in Hospitals at the 7th Annual World Patient Safety, Science & Technology Summit

For the seventh year in a row, U.S. President Bill Clinton will address healthcare leaders and deliver the closing keynote remarks at the 7th Annual World Patient Safety, Science & Technology Summit,

July 11, 2018 10:50

Takeda Receives Clearance from the United States Federal Trade Commission for the Proposed Acquisition of Shire plc

Takeda Pharmaceutical Company Limited: NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF

July 10, 2018 17:35

Boehringer Ingelheim Invests More Than €200 Million to Establish Strategic Production Center for Veterinary Public Health in France

Boehringer Ingelheim today announced an investment of more than €200 million into a new strategic production center for Veterinary Public Health. The company will establish the new site in the French

July 10, 2018 11:05

Celgene and Acceleron Announce Luspatercept Achieved Primary and All Key Secondary Endpoints in Phase III ‘BELIEVE’ Study in Adults with Transfusion-Dependent Beta-Thalassemia

Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced results from a phase III, randomized, double-blind, multi-center clinical study (BELIEVE). Luspatercept achi

July 06, 2018 14:00

Morinaga Milk Obtains Self-Affirmed GRAS Status for Its Proprietary Immunogenic Ingredient LAC-Shield™

Morinaga Milk Industry Co., Ltd., (TOKYO:2264) today announced it has attained self-affirmed GRAS (generally recognized as safe) status in the United States for LAC-Shield, a unique immunogenic ingred

July 03, 2018 18:50

New Analysis of Rekovelle® Data Further Supports Use of AMH to Personalise Fertility Treatment

Ferring Pharmaceuticals announced today a new analysis* of data from the Phase 3 ESTHER-1 trial[1] showing that natural variations in anti-Müllerian hormone (AMH) levels during and between a woman’s m

July 03, 2018 17:05

Takeda Global Headquarters Grand Opening

Takeda Pharmaceutical Company Limited, (“Takeda”) (TOKYO:4502) today held the grand opening of Takeda Global Headquarters. The building, completed in March 2018, will serve as Takeda's head office for

July 02, 2018 17:55

CHMP issues positive opinion to expand Jardiance®, Synjardy® and Glyxambi® labels to include positive effects on cardiovascular and renal outcomes

Boehringer Ingelheim and Eli Lilly and Company (NYSE:LLY) announced today that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion t

July 02, 2018 17:25

New Study Investigates the Utility of Masimo ORi™ (Oxygen Reserve Index) in Providing Early Detection of Blood Oxygenation Decrease During One-Lung Ventilation

Masimo (NASDAQ: MASI) announced today the findings of a study in which researchers evaluated the ability of Masimo ORi™ (Oxygen Reserve Index) to detect declining blood oxygenation prior to standard o

July 02, 2018 10:00

Alteogen and Lynkogen Enter into an Exclusive Option Agreement to Develop Proprietary Fusion Proteins for the Treatment of NASH and Metabolic Diseases

Alteogen Inc. (KOSDAQ:196170) and Lynkogen Inc. today announced that they have entered into an exclusive option agreement for the development of Alteogen’s novel GLP-1 mimetic and Alpha-1 Antitrypsin

June 29, 2018 17:30

World Scleroderma Day 2018: Families open up about supporting a loved one with scleroderma, in new video series

Boehringer Ingelheim today reveals a new collection of unique, personal stories and portraits from family members supporting people living with scleroderma. The collection is part of the global ‘More

June 27, 2018 17:25

New patient survey reveals: For people with atrial fibrillation, reversal of their blood thinning treatment is highly important

Results from a survey in five countries among 902 people living with atrial fibrillation (AF) reinforce the importance of patient-physician discussion around the reversal of blood thinning (anticoagul

News by Region

News by Industry